Key result
Edoxaban 30 mg once daily was superior to enoxaparin 20 mg twice daily in preventing symptomatic and asymptomatic DVT and PE following TKA and THA (5.1% vs 10.7%, P<0.001).
Why the study?
Does edoxaban reduce the composite of symptomatic and asymptomatic DVT and PE compared with enoxaparin in patients undergoing total knee or hip arthroplasty?
Population
1,326 patients undergoing total knee or hip arthroplasty in Japan and Taiwan. Mean age 68 years, mean body…
Comparison
Oral edoxaban 30 mg once daily for 11-14 days… vs Subcutaneous enoxaparin 2000 IU twice daily for…
Design
Meta-analysis, randomized, double-blind, double-dummy
Follow-up
11-14 days
Authors
Loading...
May warrant edoxaban 30 mg daily as first-line VTE prophylaxis after TKA/THA; reinforces randomized evidence in meta-analysis.
RCT (n=1,326)
double-blind, double-dummy
randomized
Yes
Does edoxaban reduce the composite of symptomatic and asymptomatic DVT and PE compared with enoxaparin in patients undergoing total knee or hip arthroplasty?
Absolute Event Rate: 5.1% vs 10.7%
p-value: p=<0.001
In a pooled analysis of patients undergoing total knee or hip arthroplasty, edoxaban 30 mg once daily was superior to enoxaparin for VTE prevention without a significant increase in bleeding.
Fuji et al. (2011) conducted an RCT in Venous thromboembolism after total knee or hip arthroplasty (n=1,326). Edoxaban vs. Enoxaparin 2000 IU (20 mg) twice daily was evaluated on Composite of symptomatic and asymptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) (p=<0.001). Edoxaban 30 mg once daily was superior to enoxaparin 20 mg twice daily in preventing symptomatic and asymptomatic DVT and PE following TKA and THA (5.1% vs 10.7%, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: